title: The impact of pharmacogenetics on the future of healthcare.
abstract: Pharmacogenetics has been promoted as potentially providing benefits to patients, managed care organizations and pharmaceutical companies. This has not translated into products that benefit healthcare developers, providers or consumers. The reasons for this are many, but this will change as the financial incentives become clear for the pharmaceutical industry to develop products that use genetic susceptibility as part of the rationale for products, healthcare providers have increasing incentive to reduce costs, and patients demand up-to-date technologies to optimize healthcare. Recent studies have established genetic contributions that alter the response to therapy for some disease entities, and more will follow as pharmacogenetics becomes increasingly accepted as an important consideration in the therapeutic decision-making process.
authors.affiliation: Sequana Therapeutics, Inc., La Jolla, CA 92130, USA. jay_lichter@sequana.com
authors.forename: J B
authors.initials: JB
authors.lastname: Lichter
authors.forename: J H
authors.initials: JH
authors.lastname: Kurth
mesh_terms: D003695:Delivery of Health Care / Q000639:trends; D015195:Drug Design; D004345:Drug Industry / Q000191:economics; D006801:Humans; D008329:Managed Care Programs / Q000191:economics; D010597:Pharmacogenetics